Latest Ask the Experts
Latest Prostate Cancer News
The variant HSD3B1 allele increases the likelihood of metastasis in men receiving androgen-deprivation therapy for biochemically recurrent disease after radiotherapy for localized PCa.
Non-metastatic prostate cancer patients are more likely to die from causes other than the disease.
Exposure to androgen-deprivation therapy was associated with a nearly 2-fold increased risk of heart failure among men without pre-existing cardiovascular disease.
Biochemical failure and prostate cancer-specific mortality rates were 13.3% and 4.9% at 10 years, respectively.
Pathologic stages T3a and T3b versus T2a were associated with 8.45 and 7.1 times increased risk of biochemical recurrence on multivariable analysis.
The later a man's testosterone level dropped below 12.1 nmol/L, the lower his lifetime risk for prostate cancer.
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.
Use of intensity-modulated radiation therapy for prostate cancer increased from 3.5% to 64% from 2002 to 2012.
In a case-control study, men who had ever used non-steroid anti-inflammatory drugs had a 23% decreased risk of prostate cancer.
Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.
Following curative treatment for localized PCa, 5-year PCa-specific survival rates are higher for patients with initial lymph node or locoregional metastases versus initial metastases in bone only or in multiple sites.
Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
The researchers found that there was no difference between the 6- and 2-fraction groups in baseline and post-implantation IPSS scores.
A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)